SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EBIO: Epoch Pharmaceuticals

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (8)12/28/2000 4:36:39 PM
From: JR   of 33
 
Tuck,
You make some good points. Only the highly visible, widely followed biotechs are acting well right now. EBIO is in neither group. Their niche is a good one, though, and they should become recognized for the company they keep...Applied Biosystems. Second deal was with Third Wave. Company is about to complete a third deal shortly.

They said the manufacturing acquisition would take 2001 revenues up from just under $4 million to $11 million with a loss of about 11 cents per share. Auerbach was showing a loss of 9 cents in 2001 on $3.8 million revenues.

The key is, how quickly they can accelerate demand for their probes. At some point between $11 to $20 million in volume, they will clearly go profitable if they control costs. The markets they serve are and will continue to grow very quickly (+30%/yr.) according to most forecasts.

$5 share purchases this week might look very good a few months out from now. Also, recent favorable mention about Epoch in NYTimes Biotech article where a fund manager was buying it recently as it was at attractive pricing below $8 or so.

Appreciate any additional information you can provide. Thanks
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext